Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

Coloplast A/S (CLPBF)

Compare
98.61
0.00
(0.00%)
At close: April 17 at 4:00:00 PM EDT
Loading Chart for CLPBF
  • Previous Close 0.00
  • Open 103.52
  • Bid 101.65 x 28000
  • Ask 107.75 x 38500
  • Day's Range 103.52 - 103.52
  • 52 Week Range 96.68 - 140.32
  • Volume 20
  • Avg. Volume 95
  • Market Cap (intraday) 24.157B
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) 30.06
  • EPS (TTM) 3.28
  • Earnings Date May 6, 2025
  • Forward Dividend & Yield 4.81 (4.88%)
  • Ex-Dividend Date Dec 6, 2024
  • 1y Target Est --

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

www.coloplast.com

16,628

Full Time Employees

September 30

Fiscal Year Ends

Recent News: CLPBF

View More

Performance Overview: CLPBF

Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

CLPBF
9.62%
OMX Copenhagen 25 Index (^OMXC25)
11.30%

1-Year Return

CLPBF
22.45%
OMX Copenhagen 25 Index (^OMXC25)
16.19%

3-Year Return

CLPBF
32.09%
OMX Copenhagen 25 Index (^OMXC25)
0.00%

5-Year Return

CLPBF
31.65%
OMX Copenhagen 25 Index (^OMXC25)
30.84%

Compare To: CLPBF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CLPBF

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    24.16B

  • Enterprise Value

    27.80B

  • Trailing P/E

    30.05

  • Forward P/E

    25.51

  • PEG Ratio (5yr expected)

    2.26

  • Price/Sales (ttm)

    5.35

  • Price/Book (mrq)

    9.50

  • Enterprise Value/Revenue

    6.64

  • Enterprise Value/EBITDA

    20.83

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.79%

  • Return on Assets (ttm)

    9.54%

  • Return on Equity (ttm)

    31.94%

  • Revenue (ttm)

    27.45B

  • Net Income Avi to Common (ttm)

    4.88B

  • Diluted EPS (ttm)

    3.28

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    906M

  • Total Debt/Equity (mrq)

    160.13%

  • Levered Free Cash Flow (ttm)

    -377.25M

Research Analysis: CLPBF

View More

Company Insights: CLPBF

Research Reports: CLPBF

View More

People Also Watch